Auxier Asset Management Has $6.86 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Auxier Asset Management increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,573 shares of the medical equipment provider’s stock after buying an additional 2,070 shares during the period. Auxier Asset Management’s holdings in Zimmer Biomet were worth $6,863,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Public Sector Pension Investment Board raised its holdings in Zimmer Biomet by 7.5% during the third quarter. Public Sector Pension Investment Board now owns 8,620 shares of the medical equipment provider’s stock worth $931,000 after buying an additional 600 shares during the last quarter. Providence Capital Advisors LLC increased its position in shares of Zimmer Biomet by 8.6% during the third quarter. Providence Capital Advisors LLC now owns 52,800 shares of the medical equipment provider’s stock worth $5,700,000 after acquiring an additional 4,191 shares in the last quarter. FORA Capital LLC raised its holdings in shares of Zimmer Biomet by 6.6% in the 3rd quarter. FORA Capital LLC now owns 38,314 shares of the medical equipment provider’s stock worth $4,136,000 after acquiring an additional 2,371 shares during the last quarter. Glenmede Trust Co. NA lifted its position in Zimmer Biomet by 163.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 44,554 shares of the medical equipment provider’s stock valued at $4,810,000 after acquiring an additional 27,673 shares in the last quarter. Finally, Townsquare Capital LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at about $341,000. 88.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the company. TD Cowen lowered their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Oppenheimer lowered their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. BTIG Research reduced their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Robert W. Baird dropped their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, UBS Group cut their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Stock Up 1.2 %

ZBH opened at $112.02 on Friday. The company has a 50 day moving average of $107.18 and a 200 day moving average of $109.50. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The company has a market cap of $22.30 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the company earned $1.65 earnings per share. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.